CTRI/2017/08/009226尚未招募未知
A randomized, double blind, placebo control study to assess the efficacy and safety of OLNP-05 capsule versus placebo for the treatment of subjects with premature ejacuation
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male subjects, aged >= 21 years to <= 60 years at the time of informed consent
- •2. Subject having a monogamous, heterosexual relationship and expected/planned to maintain this relationship for the duration of study
- •3. Subjects having baseline Intravaginal Ejaculatory Latency Time (IELT) of <2 minutes
- •4. Subjects meeting with diagnostic criteria for premature ejaculation (PEP score >=11)
- •5. Subject and his partner agreeing to attempt sexual intercourse 2 times/ week and to use stopwatch during the intercourse
- •6. Subject willing to give written informed consent and willing to comply with trial protocol
排除标准
- •1. Previous events or other conditions that may affect premature ejaculation/erectile dysfunction, including but not limited to spinal trauma or pelvic surgery
- •2. Subjects with genital anatomical deformities including but not limited to penile deformities
- •3. Subjects for whom sexual activity is inadvisable because of their underlying disease status.
- •4. Sexual dysfunction in female partner, painful intercourse, partners with decreased interest in intercourse or other forms of sexual dysfunction.
- •5. Subjects with significant and uncontrolled hematological /metabolic/ endocrinologial/ respiratory/ cardiovascular/ neurological/psychiatric/liver/ gastrointestinal/kidney diseases or other significant pathological conditions which as judged by Invesutigator may affect subject participation in the study
- •6. Any concomitant treatment which is not permissible
- •7. Continuing history of alcohol and / or drug abuse
- •8. Recent participation in another clinical trial or receive some other drug during the study besides that in the protocol that known to alter the pharmacokinetics/pharmacodynamic profile of the study drug.
- •9. Subject having a known allergy to any of the ingredients of investigational prodcut
- •10. Any other condition that in the opinion of the Investigator does not justify the subjectâ??s participation in the study.
研究者
相似试验
已完成
2 期
A study to evaluate, safety and efficacy of probiotic Unique IS2 in adults suffering from Irritable bowel syndrome in comparison with placebo.CTRI/2017/07/009170nique Biotech Limited136
撤回
2 期
A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjectsobesitasimpaired glucose tolerance1001842410019654Insulin resistanceNL-OMON37344Academisch Medisch Centrum20
进行中(未招募)
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisEUCTR2018-004705-26-ESSanofi Aventis Groupe188
进行中(未招募)
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patientsAtopic dermatitisEUCTR2018-004705-26-ITSANOFI-AVENTIS GROUPE188
进行中(未招募)
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”MedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersAtopic dermatitisEUCTR2018-004705-26-FRSanofi Aventis Groupe268
